(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer. Following developments in the mCRPC disease space, many of the same treatments have now been adopted in patients with metastatic castration sensitive disease (mCSPC). Since 2015, the addition of docetaxel, novel hormonal therapies (including abiraterone acetate, enzalutamide, and apalutmide), and local prostate-directed radiotherapy (in those with low-volume metastases) have proven benefit in patients with mCSPC. Tak is an oral selective nonsteroidal 17, 20-lyase inhibitor that blocks the synthesis of gonadal and adrenal androgens. It has previously been assessed in metastatic castration-resistant disease.